GlassScriptPhysician profile
Padma Lal
NPI 1316929433
$4,145.47
in general payments reported to CMS, 2019-2025
25 companies · $993 in 2025
The $993 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $353 · 2021: $590 · 2022: $534 · 2023: $716 · 2024: $630 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,289 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,289.17 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $872.14 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Insulinx |
| Astrazeneca Pharmaceuticals LP | $527.08 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $491.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $435.23 | 2022-2025 | Tepezza, Evenity, Prolia |
| Lilly USA, LLC | $309.76 | 2019-2024 | Mounjaro, Jardiance |
| Insulet Corporation | $232.81 | 2021-2025 | Omnipod |
| Sequel Med Tech, LLC | $223.13 | 2025 | Twiist |
| Alexion Pharmaceuticals, INC. | $160.82 | 2019-2025 | Strensiq |
| Recordati_rare_diseases_inc. | $134.41 | 2021-2025 | Isturisa, Signifor Lar |
| Radius Health, INC. | $130.56 | 2019-2023 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.32 | 2023 | Jardiance |
| Xeris Pharmaceuticals, INC. | $82.05 | 2021-2023 | Recorlev |
| Beta Bionics, INC. | $81.69 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Corcept Therapeutics | $50.40 | 2023-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $43.82 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $41.53 | 2022 | |
| Pfizer INC. | $38.10 | 2019-2025 | |
| Cequr Corporation | $32.24 | 2023 | Cequr Simplicity |
| Medtronic Minimed, INC. | $30.44 | 2019 | |
| Amneal Pharmaceuticals LLC | $28.35 | 2024 | Unithroid |
| Dexcom, INC. | $24.02 | 2024 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $21.89 | 2023 | Tepezza |
| Abbvie INC. | $19.78 | 2022 | |
| Amryt Pharma Holdings LTD | $15.21 | 2023 | Mycapssa |
| Eusa Pharma (US) LLC | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padma Lal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.